Is transcutaneous oxygen and carbon dioxide monitoring indispensable in short- and long-term therapeutic management of non-reconstructable lower critical limb ischemia?

The aim of this study was to evaluate the capacity of transcutaneous partial pressure of O(2) (TCpO(2)) and CO(2) (TCpCO(2)) to predict clinical response to pharmacological treatment in short- and long-term follow-up of unreconstructable critical limb ischemia (CLI) treated with prostanoids; to sugg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Minerva cardioangiologica Jg. 54; H. 4; S. 481
Hauptverfasser: Melillo, E, Nuti, M, Pedrinelli, R, Buttitta, F, Balbarini, A
Format: Journal Article
Sprache:Englisch
Italienisch
Veröffentlicht: Italy 01.08.2006
Schlagworte:
ISSN:0026-4725
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract The aim of this study was to evaluate the capacity of transcutaneous partial pressure of O(2) (TCpO(2)) and CO(2) (TCpCO(2)) to predict clinical response to pharmacological treatment in short- and long-term follow-up of unreconstructable critical limb ischemia (CLI) treated with prostanoids; to suggest a diagnostic and therapeutic algorithm able to define the possibility of prostanoid therapy in unreconstructable CLI at high risk of limb loss. Twenty-six consecutive patients with CLI (21 with distal trophic lesions, 31 symptomatic limbs) considered unreconstructable after peripheral angiography and with a history of type 2 diabetes mellitus underwent daily parenteral Iloprost treatment for 2-3 weeks. Transcutaneous gas-analytic monitoring (TGM) in non-reconstructable CLI treated with Iloprost divided patients into 2 groups: early responders (ER) with increased TcpO(2) and normalization of TcpCO2, and non responders (NR) with unchanged TcpO(2) and TcpCO(2) parameters. In the NR who underwent a second cycle of Iloprost within a few months of the first, TGM further divided the patients into another subgroup of late responders (LR) with TcpO(2) and TcpCO(2) similar to the ER group and a subgroup of NR, who, after pharmacological treatment failure, should undergo eventual surgical re-timing and/or spinal cord stimulation in a final attempt to save the limb. In the short-term follow-up of CLI, a marked reduction in supine/dependent TcpO(2) and a marked increase in supine TcpCO(2) at the symptomatic forefoot proved to be significant predictors of major amputation risk. In the long-term follow-up period, TGM showed that, in ER and in LR, the favourable effect of pharmacological therapy observed in the first 6 months will disappear over the next 6 months, suggesting an algorithm of 2- to 3-week cycles of prostanoid therapy repeated every year. In NR treated with surgical and/or alternative therapies who did not undergo major amputations, prolonged instrumental TGM will provide a constant evaluation of metabolic parameters, thus providing the possibility to save the limb with additional pharmacological therapy.
AbstractList The aim of this study was to evaluate the capacity of transcutaneous partial pressure of O(2) (TCpO(2)) and CO(2) (TCpCO(2)) to predict clinical response to pharmacological treatment in short- and long-term follow-up of unreconstructable critical limb ischemia (CLI) treated with prostanoids; to suggest a diagnostic and therapeutic algorithm able to define the possibility of prostanoid therapy in unreconstructable CLI at high risk of limb loss. Twenty-six consecutive patients with CLI (21 with distal trophic lesions, 31 symptomatic limbs) considered unreconstructable after peripheral angiography and with a history of type 2 diabetes mellitus underwent daily parenteral Iloprost treatment for 2-3 weeks. Transcutaneous gas-analytic monitoring (TGM) in non-reconstructable CLI treated with Iloprost divided patients into 2 groups: early responders (ER) with increased TcpO(2) and normalization of TcpCO2, and non responders (NR) with unchanged TcpO(2) and TcpCO(2) parameters. In the NR who underwent a second cycle of Iloprost within a few months of the first, TGM further divided the patients into another subgroup of late responders (LR) with TcpO(2) and TcpCO(2) similar to the ER group and a subgroup of NR, who, after pharmacological treatment failure, should undergo eventual surgical re-timing and/or spinal cord stimulation in a final attempt to save the limb. In the short-term follow-up of CLI, a marked reduction in supine/dependent TcpO(2) and a marked increase in supine TcpCO(2) at the symptomatic forefoot proved to be significant predictors of major amputation risk. In the long-term follow-up period, TGM showed that, in ER and in LR, the favourable effect of pharmacological therapy observed in the first 6 months will disappear over the next 6 months, suggesting an algorithm of 2- to 3-week cycles of prostanoid therapy repeated every year. In NR treated with surgical and/or alternative therapies who did not undergo major amputations, prolonged instrumental TGM will provide a constant evaluation of metabolic parameters, thus providing the possibility to save the limb with additional pharmacological therapy.
The aim of this study was to evaluate the capacity of transcutaneous partial pressure of O(2) (TCpO(2)) and CO(2) (TCpCO(2)) to predict clinical response to pharmacological treatment in short- and long-term follow-up of unreconstructable critical limb ischemia (CLI) treated with prostanoids; to suggest a diagnostic and therapeutic algorithm able to define the possibility of prostanoid therapy in unreconstructable CLI at high risk of limb loss.AIMThe aim of this study was to evaluate the capacity of transcutaneous partial pressure of O(2) (TCpO(2)) and CO(2) (TCpCO(2)) to predict clinical response to pharmacological treatment in short- and long-term follow-up of unreconstructable critical limb ischemia (CLI) treated with prostanoids; to suggest a diagnostic and therapeutic algorithm able to define the possibility of prostanoid therapy in unreconstructable CLI at high risk of limb loss.Twenty-six consecutive patients with CLI (21 with distal trophic lesions, 31 symptomatic limbs) considered unreconstructable after peripheral angiography and with a history of type 2 diabetes mellitus underwent daily parenteral Iloprost treatment for 2-3 weeks.METHODSTwenty-six consecutive patients with CLI (21 with distal trophic lesions, 31 symptomatic limbs) considered unreconstructable after peripheral angiography and with a history of type 2 diabetes mellitus underwent daily parenteral Iloprost treatment for 2-3 weeks.Transcutaneous gas-analytic monitoring (TGM) in non-reconstructable CLI treated with Iloprost divided patients into 2 groups: early responders (ER) with increased TcpO(2) and normalization of TcpCO2, and non responders (NR) with unchanged TcpO(2) and TcpCO(2) parameters. In the NR who underwent a second cycle of Iloprost within a few months of the first, TGM further divided the patients into another subgroup of late responders (LR) with TcpO(2) and TcpCO(2) similar to the ER group and a subgroup of NR, who, after pharmacological treatment failure, should undergo eventual surgical re-timing and/or spinal cord stimulation in a final attempt to save the limb.RESULTSTranscutaneous gas-analytic monitoring (TGM) in non-reconstructable CLI treated with Iloprost divided patients into 2 groups: early responders (ER) with increased TcpO(2) and normalization of TcpCO2, and non responders (NR) with unchanged TcpO(2) and TcpCO(2) parameters. In the NR who underwent a second cycle of Iloprost within a few months of the first, TGM further divided the patients into another subgroup of late responders (LR) with TcpO(2) and TcpCO(2) similar to the ER group and a subgroup of NR, who, after pharmacological treatment failure, should undergo eventual surgical re-timing and/or spinal cord stimulation in a final attempt to save the limb.In the short-term follow-up of CLI, a marked reduction in supine/dependent TcpO(2) and a marked increase in supine TcpCO(2) at the symptomatic forefoot proved to be significant predictors of major amputation risk. In the long-term follow-up period, TGM showed that, in ER and in LR, the favourable effect of pharmacological therapy observed in the first 6 months will disappear over the next 6 months, suggesting an algorithm of 2- to 3-week cycles of prostanoid therapy repeated every year. In NR treated with surgical and/or alternative therapies who did not undergo major amputations, prolonged instrumental TGM will provide a constant evaluation of metabolic parameters, thus providing the possibility to save the limb with additional pharmacological therapy.CONCLUSIONSIn the short-term follow-up of CLI, a marked reduction in supine/dependent TcpO(2) and a marked increase in supine TcpCO(2) at the symptomatic forefoot proved to be significant predictors of major amputation risk. In the long-term follow-up period, TGM showed that, in ER and in LR, the favourable effect of pharmacological therapy observed in the first 6 months will disappear over the next 6 months, suggesting an algorithm of 2- to 3-week cycles of prostanoid therapy repeated every year. In NR treated with surgical and/or alternative therapies who did not undergo major amputations, prolonged instrumental TGM will provide a constant evaluation of metabolic parameters, thus providing the possibility to save the limb with additional pharmacological therapy.
Author Balbarini, A
Pedrinelli, R
Melillo, E
Nuti, M
Buttitta, F
Author_xml – sequence: 1
  givenname: E
  surname: Melillo
  fullname: Melillo, E
  email: e.melillo@ao-pisa.toscana.it
  organization: Angiology Unit, Cardio-Thoracic Department Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. e.melillo@ao-pisa.toscana.it
– sequence: 2
  givenname: M
  surname: Nuti
  fullname: Nuti, M
– sequence: 3
  givenname: R
  surname: Pedrinelli
  fullname: Pedrinelli, R
– sequence: 4
  givenname: F
  surname: Buttitta
  fullname: Buttitta, F
– sequence: 5
  givenname: A
  surname: Balbarini
  fullname: Balbarini, A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17016419$$D View this record in MEDLINE/PubMed
BookMark eNo1kMtqwzAQRbVIaR7tLxStujNYfsjRqpTQRyDQTfZmLI0dFUtyJZkmf9TPrJukq-HCmcvlLMnMOoszskjTjCdFlZVzsgzhc4o5E-yWzFmVMl4wsSA_20CjBxvkGMGiGwN1x1OHloJVVIJvnKVKu6NWSI2zOjqvbUe1VToMaAM0PU6JhoPzMTl_9c52SURvaDyghwHHqCU1YKFDgzZS19JpYeJROhuiH2U8t_TuGz2VXk849LTXpqE6yAMaDU935KaFPuD99a7I_vVlv3lPdh9v283zLhnKQiRt3lSgyhQZyioHKaoshQJVo7jkQkCmipavecXX6xJFVWIKed6yrOWTmkLwbEUeL7WDd18jhlibaQL2_UVOzdciz0r2Bz5cwbExqOrBawP-VP-rzX4Bp0J64Q
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
ExternalDocumentID 17016419
Genre Journal Article
GroupedDBID 53G
AENEX
ALMA_UNASSIGNED_HOLDINGS
CGR
CUY
CVF
EBS
ECM
EIF
EJD
F5P
NPM
ZGI
ZXP
7X8
ID FETCH-LOGICAL-p549-f3b7ad50e1ec73ac9720a4edbd6c699a2d4f68676885e975e0a33f12f62314962
IEDL.DBID 7X8
ISSN 0026-4725
IngestDate Fri Jul 11 05:28:45 EDT 2025
Sat Sep 28 07:53:49 EDT 2024
IsPeerReviewed false
IsScholarly false
Issue 4
Language English
Italian
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p549-f3b7ad50e1ec73ac9720a4edbd6c699a2d4f68676885e975e0a33f12f62314962
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 17016419
PQID 68932516
PQPubID 23479
ParticipantIDs proquest_miscellaneous_68932516
pubmed_primary_17016419
PublicationCentury 2000
PublicationDate 2006-Aug
20060801
PublicationDateYYYYMMDD 2006-08-01
PublicationDate_xml – month: 08
  year: 2006
  text: 2006-Aug
PublicationDecade 2000
PublicationPlace Italy
PublicationPlace_xml – name: Italy
PublicationTitle Minerva cardioangiologica
PublicationTitleAlternate Minerva Cardioangiol
PublicationYear 2006
SSID ssj0023191
Score 1.3918254
Snippet The aim of this study was to evaluate the capacity of transcutaneous partial pressure of O(2) (TCpO(2)) and CO(2) (TCpCO(2)) to predict clinical response to...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 481
SubjectTerms Aged
Aged, 80 and over
Blood Gas Monitoring, Transcutaneous
Critical Illness
Female
Humans
Iloprost - therapeutic use
Ischemia - blood
Ischemia - drug therapy
Leg - blood supply
Male
Middle Aged
Time Factors
Vasodilator Agents - therapeutic use
Title Is transcutaneous oxygen and carbon dioxide monitoring indispensable in short- and long-term therapeutic management of non-reconstructable lower critical limb ischemia?
URI https://www.ncbi.nlm.nih.gov/pubmed/17016419
https://www.proquest.com/docview/68932516
Volume 54
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAMrDwEK_yvIHVookTJ5aQKoRAMFB1YOhW-RWI1CalLaj8I34md0mKWBADS6QMtiz7fPd9Pvs-xi5ikwbeBYIHwnQ4RjzNtU4jroTKnBQSuY-pxCaSXi8dDFR_hV0t38LQtcqlT6wctSstnZFfSgysGItld_LKSTOKcquNgMYqawkEMrQtk8F3DgGBS6OXF0oeJWH8O4asYsnd1v9Gsc02GwwJ1_Wi77CWLyCf77LPhxnMKfbYN4R8Hjk9lIsPtBDQhQOrp6YswOXlIncextVmplM9oLT1bIJ8lp5R4R_MXhCU86rVqCyeOblv-PFSC8bfl2agzKAoC14R67oYbdXLiNTXwDZCCjDKxwZyZNJ-nOvuHnu6u326ueeNEgOfIH_kmTCJdnHHB94mQluVhB0deWectFIpHbook6lE5pLGXiWx72ghsiDMEFshA5PhPlvDofhDBiJSJnWUrQyzSFDxQfTJJpHWqJhK8bXZ-XLih2jolL2oJ2y4nPo2O6jXbjip63EMqaS8jAJ19GfbY7ZRH6HQBb4T1spwi_tTtm7f5_lselbZD357_ccvKLbW5g
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Is+transcutaneous+oxygen+and+carbon+dioxide+monitoring+indispensable+in+short-+and+long-term+therapeutic+management+of+non-reconstructable+lower+critical+limb+ischemia%3F&rft.jtitle=Minerva+cardioangiologica&rft.au=Melillo%2C+E&rft.au=Nuti%2C+M&rft.au=Pedrinelli%2C+R&rft.au=Buttitta%2C+F&rft.date=2006-08-01&rft.issn=0026-4725&rft.volume=54&rft.issue=4&rft.spage=481&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0026-4725&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0026-4725&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0026-4725&client=summon